开云app官网登录入口网页版-官方正版

#Checkmate#

50篇内容 | 1637人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2025242, encodeId=42bf2025242e2, content=<a href='/topic/show?id=eeeb459812' target=_blank style='color:#2F92EE;'>#Checkmate#</a>, objectTitle=III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期, objectType=article, longId=301595, objectId=0e1630159509, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e1630159509, replyNumber=0, likeNumber=85, createdTime=2022-06-09, rootId=0, userName=chenwq08, userId=365d170, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e1630159509, moduleTitle=III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0e1630159509)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2025237, encodeId=ff6b202523ee5, content=<a href='/topic/show?id=eeeb459812' target=_blank style='color:#2F92EE;'>#Checkmate#</a>, objectTitle=Ann Oncol：一线nivolumab + ipilimumab vs化疗治疗不可切除的恶性胸膜间皮瘤的疗效:CheckMate 743的3年生存结果, objectType=article, longId=295347, objectId=691929534ef4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=691929534ef4, replyNumber=0, likeNumber=68, createdTime=2022-03-05, rootId=0, userName=chenwq08, userId=365d170, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=691929534ef4, moduleTitle=Ann Oncol：一线nivolumab + ipilimumab vs化疗治疗不可切除的恶性胸膜间皮瘤的疗效:CheckMate 743的3年生存结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=691929534ef4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2025238, encodeId=e636202523853, content=<a href='/topic/show?id=eeeb459812' target=_blank style='color:#2F92EE;'>#Checkmate#</a>, objectTitle=Oncologist：CheckMate 141亚组分析比较nivolumab（那武利尤单抗）和化疗治疗复发或转移性头颈部鳞状细胞癌（R/M SCCHN）患者的疗效, objectType=article, longId=299383, objectId=8ef92993836d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ef92993836d, replyNumber=0, likeNumber=100, createdTime=2022-08-19, rootId=0, userName=chenwq08, userId=365d170, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ef92993836d, moduleTitle=Oncologist：CheckMate 141亚组分析比较nivolumab（那武利尤单抗）和化疗治疗复发或转移性头颈部鳞状细胞癌（R/M SCCHN）患者的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8ef92993836d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2025241, encodeId=a732202524138, content=<a href='/topic/show?id=eeeb459812' target=_blank style='color:#2F92EE;'>#Checkmate#</a>, objectTitle=Cancer：纳武单抗联合伊匹单抗治疗晚期肾细胞癌伴有脑转移患者的安全性和有效性（CheckMate 920）, objectType=article, longId=723571, objectId=265ee235713c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=265ee235713c, replyNumber=0, likeNumber=72, createdTime=2023-02-17, rootId=0, userName=chenwq08, userId=365d170, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=265ee235713c, moduleTitle=Cancer：纳武单抗联合伊匹单抗治疗晚期肾细胞癌伴有脑转移患者的安全性和有效性（CheckMate 920）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=265ee235713c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2025235, encodeId=5e98202523591, content=<a href='/topic/show?id=eeeb459812' target=_blank style='color:#2F92EE;'>#Checkmate#</a>, objectTitle=CheckMate-743 III期研究结果：一线治疗不可切除的恶性胸膜间皮瘤，纳武利尤单抗联合伊匹木单抗显示出持久获益, objectType=article, longId=217090, objectId=179321e09027, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=179321e09027, replyNumber=0, likeNumber=80, createdTime=2022-07-13, rootId=0, userName=chenwq08, userId=365d170, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=179321e09027, moduleTitle=CheckMate-743 III期研究结果：一线治疗不可切除的恶性胸膜间皮瘤，纳武利尤单抗联合伊匹木单抗显示出持久获益, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=179321e09027)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2025240, encodeId=d12c202524015, content=<a href='/topic/show?id=eeeb459812' target=_blank style='color:#2F92EE;'>#Checkmate#</a>, objectTitle=ESMO：纳武利尤单抗联合化疗新辅助治疗能降低可切除非小细胞肺癌患者EFS风险43%（Checkmate-816研究）, objectType=article, longId=301717, objectId=e006301e1776, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e006301e1776, replyNumber=0, likeNumber=115, createdTime=2022-07-21, rootId=0, userName=chenwq08, userId=365d170, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e006301e1776, moduleTitle=ESMO：纳武利尤单抗联合化疗新辅助治疗能降低可切除非小细胞肺癌患者EFS风险43%（Checkmate-816研究）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e006301e1776)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2025239, encodeId=b2d32025239d3, content=<a href='/topic/show?id=eeeb459812' target=_blank style='color:#2F92EE;'>#Checkmate#</a>, objectTitle=J Immunother Cancer：CheckMate 920研究评估nivolumab(那武利尤单抗)+ ipilimumab (伊匹木单抗)治疗晚期非透明细胞肾癌患者的疗效和安全性, objectType=article, longId=299733, objectId=15e0299e3314, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15e0299e3314, replyNumber=0, likeNumber=84, createdTime=2022-03-16, rootId=0, userName=chenwq08, userId=365d170, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15e0299e3314, moduleTitle=J Immunother Cancer：CheckMate 920研究评估nivolumab(那武利尤单抗)+ ipilimumab (伊匹木单抗)治疗晚期非透明细胞肾癌患者的疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=15e0299e3314)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2025233, encodeId=51ba20252330c, content=<a href='/topic/show?id=eeeb459812' target=_blank style='color:#2F92EE;'>#Checkmate#</a>, objectTitle=Ann Oncol: 纳武利尤单抗（Nivolumab）二线治疗并不能改善小细胞肺癌的预后：来自CheckMate 331临床研究, objectType=article, longId=212154, objectId=c931212154fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c931212154fa, replyNumber=0, likeNumber=84, createdTime=2022-02-04, rootId=0, userName=chenwq08, userId=365d170, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c931212154fa, moduleTitle=Ann Oncol: 纳武利尤单抗（Nivolumab）二线治疗并不能改善小细胞肺癌的预后：来自CheckMate 331临床研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c931212154fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2025232, encodeId=ee0b202523212, content=<a href='/topic/show?id=eeeb459812' target=_blank style='color:#2F92EE;'>#Checkmate#</a>, objectTitle=百时美施贵宝公布III期临床研究CheckMate -9LA两年随访数据，结果喜人！, objectType=article, longId=210359, objectId=837e210359f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=837e210359f2, replyNumber=0, likeNumber=73, createdTime=2021-11-24, rootId=0, userName=chenwq08, userId=365d170, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=837e210359f2, moduleTitle=百时美施贵宝公布III期临床研究CheckMate -9LA两年随访数据，结果喜人！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=837e210359f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2025236, encodeId=ffa320252363f, content=<a href='/topic/show?id=eeeb459812' target=_blank style='color:#2F92EE;'>#Checkmate#</a>, objectTitle=CheckMate-816 III期数据公布：非小细胞肺癌患者新辅助治疗，纳武利尤单抗联合化疗可显著改善无事件生存期, objectType=article, longId=220045, objectId=0f6e220045c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f6e220045c5, replyNumber=0, likeNumber=77, createdTime=2022-01-19, rootId=0, userName=chenwq08, userId=365d170, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f6e220045c5, moduleTitle=CheckMate-816 III期数据公布：非小细胞肺癌患者新辅助治疗，纳武利尤单抗联合化疗可显著改善无事件生存期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0f6e220045c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2025231, encodeId=4261202523166, content=<a href='/topic/show?id=eeeb459812' target=_blank style='color:#2F92EE;'>#Checkmate#</a>, objectTitle=百时美施贵宝公布了III期临床研究CheckMate -227第1部分随访结果, objectType=article, longId=210709, objectId=659b210e098a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=659b210e098a, replyNumber=0, likeNumber=0, createdTime=2021-06-06, rootId=0, userName=chenwq08, userId=365d170, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=659b210e098a, moduleTitle=百时美施贵宝公布了III期临床研究CheckMate -227第1部分随访结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=659b210e098a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2025230, encodeId=a6052025230e0, content=<a href='/topic/show?id=eeeb459812' target=_blank style='color:#2F92EE;'>#Checkmate#</a>, objectTitle=III期临床研究CheckMate -816结果发布：欧狄沃®（纳武利尤单抗）联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善肿瘤病理完全缓解, objectType=article, longId=209763, objectId=515e209e63ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=515e209e63ce, replyNumber=0, likeNumber=111, createdTime=2021-11-05, rootId=0, userName=chenwq08, userId=365d170, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=515e209e63ce, moduleTitle=III期临床研究CheckMate -816结果发布：欧狄沃®（纳武利尤单抗）联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善肿瘤病理完全缓解, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=515e209e63ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2025234, encodeId=f2ce2025234d2, content=<a href='/topic/show?id=eeeb459812' target=_blank style='color:#2F92EE;'>#Checkmate#</a>, objectTitle=ASCO2021: Nivolumab + Ipilimumab可使晚期NSCLC患者获益（CheckMate-227的4年数据）, objectType=article, longId=212499, objectId=bef02124990d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bef02124990d, replyNumber=0, likeNumber=59, createdTime=2022-04-22, rootId=0, userName=chenwq08, userId=365d170, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bef02124990d, moduleTitle=ASCO2021: Nivolumab + Ipilimumab可使晚期NSCLC患者获益（CheckMate-227的4年数据）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=bef02124990d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2025225, encodeId=ddef2025225d9, content=<a href='/topic/show?id=eeeb459812' target=_blank style='color:#2F92EE;'>#Checkmate#</a>, objectTitle=食管癌及胃食管连接部癌术后欧狄沃（纳武利尤单抗）辅助治疗III期临床研究CheckMate -577达到主要终点无病生存期, objectType=article, longId=199310, objectId=a5e8199310d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5e8199310d0, replyNumber=0, likeNumber=60, createdTime=2021-01-20, rootId=0, userName=chenwq08, userId=365d170, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5e8199310d0, moduleTitle=食管癌及胃食管连接部癌术后欧狄沃（纳武利尤单抗）辅助治疗III期临床研究CheckMate -577达到主要终点无病生存期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a5e8199310d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2025226, encodeId=71fe20252266a, content=<a href='/topic/show?id=eeeb459812' target=_blank style='color:#2F92EE;'>#Checkmate#</a>, objectTitle=JCO：CheckMate 066试验| 纳武单抗治疗晚期黑色素瘤的5年随访结果, objectType=article, longId=201677, objectId=01c02016e7b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01c02016e7b3, replyNumber=0, likeNumber=69, createdTime=2020-10-25, rootId=0, userName=chenwq08, userId=365d170, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01c02016e7b3, moduleTitle=JCO：CheckMate 066试验| 纳武单抗治疗晚期黑色素瘤的5年随访结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=01c02016e7b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2025229, encodeId=ded320252298b, content=<a href='/topic/show?id=eeeb459812' target=_blank style='color:#2F92EE;'>#Checkmate#</a>, objectTitle=ASCO GU 2021: Nivolumab联合Cabozantinib与舒尼替尼在晚期肾细胞癌中效果对比（CheckMate 9ER研究）, objectType=article, longId=207196, objectId=04c620e196a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04c620e196a7, replyNumber=0, likeNumber=79, createdTime=2021-08-01, rootId=0, userName=chenwq08, userId=365d170, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04c620e196a7, moduleTitle=ASCO GU 2021: Nivolumab联合Cabozantinib与舒尼替尼在晚期肾细胞癌中效果对比（CheckMate 9ER研究）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=04c620e196a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2025228, encodeId=daec2025228bf, content=<a href='/topic/show?id=eeeb459812' target=_blank style='color:#2F92EE;'>#Checkmate#</a>, objectTitle=纳武利尤单抗用于根治手术后高复发风险肌层浸润性尿路上皮癌治疗取得成功（CheckMate -274研究）, objectType=article, longId=207160, objectId=c47f20e16003, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c47f20e16003, replyNumber=0, likeNumber=71, createdTime=2022-01-08, rootId=0, userName=chenwq08, userId=365d170, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c47f20e16003, moduleTitle=纳武利尤单抗用于根治手术后高复发风险肌层浸润性尿路上皮癌治疗取得成功（CheckMate -274研究）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c47f20e16003)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2025219, encodeId=58d92025219f6, content=<a href='/topic/show?id=eeeb459812' target=_blank style='color:#2F92EE;'>#Checkmate#</a>, objectTitle=CheckMate-743试验中期分析显示：纳武利尤单抗联合伊匹木单抗治疗恶性胸膜间皮瘤3期试验达主要终点, objectType=article, longId=192692, objectId=46461926922a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46461926922a, replyNumber=0, likeNumber=77, createdTime=2021-04-01, rootId=0, userName=chenwq08, userId=365d170, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46461926922a, moduleTitle=CheckMate-743试验中期分析显示：纳武利尤单抗联合伊匹木单抗治疗恶性胸膜间皮瘤3期试验达主要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=46461926922a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2025221, encodeId=76902025221d4, content=<a href='/topic/show?id=eeeb459812' target=_blank style='color:#2F92EE;'>#Checkmate#</a>, objectTitle=CheckMate -9LA临床试验数据积极！欧狄沃（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗显著提高一线转移性非小细胞肺癌患者总生存, objectType=article, longId=194157, objectId=c3b319415e0d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3b319415e0d, replyNumber=0, likeNumber=62, createdTime=2021-04-19, rootId=0, userName=chenwq08, userId=365d170, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3b319415e0d, moduleTitle=CheckMate -9LA临床试验数据积极！欧狄沃（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗显著提高一线转移性非小细胞肺癌患者总生存, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c3b319415e0d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2025227, encodeId=8a2c202522eea, content=<a href='/topic/show?id=eeeb459812' target=_blank style='color:#2F92EE;'>#Checkmate#</a>, objectTitle=CheckMate–816达到病理完全缓解的主要研究终点，患者术前接受欧狄沃联合化疗改善肿瘤病理完全缓解, objectType=article, longId=201902, objectId=51d220190295, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51d220190295, replyNumber=0, likeNumber=85, createdTime=2020-10-18, rootId=0, userName=chenwq08, userId=365d170, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51d220190295, moduleTitle=CheckMate–816达到病理完全缓解的主要研究终点，患者术前接受欧狄沃联合化疗改善肿瘤病理完全缓解, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=51d220190295)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

Checkmate

2020-05-29

chenwq08 (审核中...)

前往app查看评论内容

#Checkmate#

III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期

2022-06-09

chenwq08 (审核中...)

前往app查看评论内容

#Checkmate#

Ann Oncol：一线nivolumab + ipilimumab vs化疗治疗不可切除的恶性胸膜间皮瘤的疗效:CheckMate 743的3年生存结果

2022-03-05

chenwq08 (审核中...)

前往app查看评论内容

#Checkmate#

Oncologist：CheckMate 141亚组分析比较nivolumab（那武利尤单抗）和化疗治疗复发或转移性头颈部鳞状细胞癌（R/M SCCHN）患者的疗效

2022-08-19

chenwq08 (审核中...)

前往app查看评论内容

#Checkmate#

Cancer：纳武单抗联合伊匹单抗治疗晚期肾细胞癌伴有脑转移患者的安全性和有效性（CheckMate 920）

2023-02-17

chenwq08 (审核中...)

前往app查看评论内容

#Checkmate#

CheckMate-743 III期研究结果：一线治疗不可切除的恶性胸膜间皮瘤，纳武利尤单抗联合伊匹木单抗显示出持久获益

2022-07-13

chenwq08 (审核中...)

前往app查看评论内容

#Checkmate#

ESMO：纳武利尤单抗联合化疗新辅助治疗能降低可切除非小细胞肺癌患者EFS风险43%（Checkmate-816研究）

2022-07-21

chenwq08 (审核中...)

前往app查看评论内容

#Checkmate#

J Immunother Cancer：CheckMate 920研究评估nivolumab(那武利尤单抗)+ ipilimumab (伊匹木单抗)治疗晚期非透明细胞肾癌患者的疗效和安全性

2022-03-16

chenwq08 (审核中...)

前往app查看评论内容

#Checkmate#

Ann Oncol: 纳武利尤单抗（Nivolumab）二线治疗并不能改善小细胞肺癌的预后：来自CheckMate 331临床研究

2022-02-04

chenwq08 (审核中...)

前往app查看评论内容

#Checkmate#

百时美施贵宝公布III期临床研究CheckMate -9LA两年随访数据，结果喜人！

2021-11-24

chenwq08 (审核中...)

前往app查看评论内容

#Checkmate#

CheckMate-816 III期数据公布：非小细胞肺癌患者新辅助治疗，纳武利尤单抗联合化疗可显著改善无事件生存期

2022-01-19

chenwq08 (审核中...)

前往app查看评论内容

#Checkmate#

百时美施贵宝公布了III期临床研究CheckMate -227第1部分随访结果

2021-06-06

chenwq08 (审核中...)

前往app查看评论内容

#Checkmate#

III期临床研究CheckMate -816结果发布：欧狄沃®（纳武利尤单抗）联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善肿瘤病理完全缓解

2021-11-05

chenwq08 (审核中...)

前往app查看评论内容

#Checkmate#

ASCO2021: Nivolumab + Ipilimumab可使晚期NSCLC患者获益（CheckMate-227的4年数据）

2022-04-22

chenwq08 (审核中...)

前往app查看评论内容

#Checkmate#

食管癌及胃食管连接部癌术后欧狄沃（纳武利尤单抗）辅助治疗III期临床研究CheckMate -577达到主要终点无病生存期

2021-01-20

chenwq08 (审核中...)

前往app查看评论内容

#Checkmate#

JCO：CheckMate 066试验| 纳武单抗治疗晚期黑色素瘤的5年随访结果

2020-10-25

chenwq08 (审核中...)

前往app查看评论内容

#Checkmate#

ASCO GU 2021: Nivolumab联合Cabozantinib与舒尼替尼在晚期肾细胞癌中效果对比（CheckMate 9ER研究）

2021-08-01

chenwq08 (审核中...)

前往app查看评论内容

#Checkmate#

纳武利尤单抗用于根治手术后高复发风险肌层浸润性尿路上皮癌治疗取得成功（CheckMate -274研究）

2022-01-08

chenwq08 (审核中...)

前往app查看评论内容

#Checkmate#

CheckMate-743试验中期分析显示：纳武利尤单抗联合伊匹木单抗治疗恶性胸膜间皮瘤3期试验达主要终点

2021-04-01

chenwq08 (审核中...)

前往app查看评论内容

#Checkmate#

CheckMate -9LA临床试验数据积极！欧狄沃（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗显著提高一线转移性非小细胞肺癌患者总生存

2021-04-19

chenwq08 (审核中...)

前往app查看评论内容

#Checkmate#

CheckMate–816达到病理完全缓解的主要研究终点，患者术前接受欧狄沃联合化疗改善肿瘤病理完全缓解

2020-10-18

科室
- - 订阅+
  - 更多科室
工具
服务